Nama's AI scorecard currently rates Medline Hold (5.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is MDLN's P/E ratio?

Medline trades at a trailing price-to-earnings ratio of 25.1.

When does MDLN report earnings?

Medline's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.40.

What is the MDLN price target?

The median analyst price target from 26 analysts is $45.00, with a range of $34.00 – $55.00.

Is MDLN Shariah compliant?

Nama's AAOIFI-style screen reads Medline as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Medline (MDLN)

Healthcare · Medical Instruments Supplies · NASDAQ

Medline (MDLN) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $52.17B, a trailing price-to-earnings ratio of 25.1 and a free-cash-flow yield of 4.0%. Nama's AI scorecard rates it Hold, 5.0 out of 10.

AI scorecard

Hold · 5.0/10

The sections balance. As of Nov 7, 2026.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-22.1%

How far the last close sits under the highest price of the past five years.

Market cap	$52.17B
Trailing P/E	25.1
Price / book	3.0
Price / sales	1.8
FCF yield	4.0%
Dividend yield	—
Gross margin	26.4%
Operating margin	6.2%
Net margin	2.4%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	—
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Instruments Supplies

MDLN earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.40). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.44	$0.35	+25.7%	$7.86B
Q2 2026	Aug 5, 2026	$0.50	$0.32	+56.2%	$7.68B
Q1 2026	May 6, 2026	$0.33	$0.29	+13.8%	$7.35B
Q4 2025	Feb 25, 2026	$0.31	$0.24	+29.2%	$7.79B

MDLN analyst price target

Median target $45.00 from 26 analysts, ranging $34.00 – $55.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3
COO	Cooper Companies	$11.86B	13.5

Explore live MDLN data on Nama Insights →

MDLN FAQ

Is MDLN a buy?: Nama's AI scorecard currently rates Medline Hold (5.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is MDLN's P/E ratio?: Medline trades at a trailing price-to-earnings ratio of 25.1.
When does MDLN report earnings?: Medline's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.40.
What is the MDLN price target?: The median analyst price target from 26 analysts is $45.00, with a range of $34.00 – $55.00.
Is MDLN Shariah compliant?: Nama's AAOIFI-style screen reads Medline as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.